New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
10:41 EDTG, AZNGenpact's AstraZeneca deal indicates enviroment improving, says Goldman
Goldman sad Genpact's deal to provide financing and accounting services to AstraZeneca indicates the deal environment is improving and that Genpact is making progress getting through the pipeline.
News For G;AZN From The Last 14 Days
Check below for free stories on G;AZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:19 EDTAZNLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTAZNPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 8, 2014
11:03 EDTAZNPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
08:26 EDTGGenpact accepted payments for $302.6M from modified "Dutch Auction" offer
Genpact announced the final results of its modified "Dutch Auction" self-tender offer for the purchase of up to $300M in value of its common shares, which expired at 12:00 Midnight, New York City time, at the end of the day on April 2. Based on the final count by Computershare Trust Company, N.A., the depositary for the tender offer, Genpact accepted for payment an aggregate of 17,292,842 common shares at a final purchase price of $17.50 per share, for an aggregate cost of approximately $302.6M, excluding fees and expenses relating to the tender offer. The shares accepted for purchase in the tender offer include shares accepted through Genpact's exercise of its right to upsize the tender offer by up to 2% of its outstanding shares.
April 7, 2014
16:34 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
07:27 EDTAZNAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
05:48 EDTAZNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use